Document Detail


Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
MedLine Citation:
PMID:  20806126     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
AZD0837, currently in clinical development, is a once-daily oral anticoagulant that is bioconverted to AR-H067637, a selective, reversible direct thrombin inhibitor (DTI). When developing a new DTI, the antithrombotic effects are commonly investigated in in vivo animal models; this report shows the effect of AR-H067637 in venous and arterial thrombosis and bleeding models in anaesthetised rats. Thrombus formation was induced by topical application of ferric chloride to the carotid artery or to the caval vein with partial stasis. Cutaneous incision bleeding time and muscle transection blood loss were assessed, with or without acetylsalicylic acid (ASA). Activated partial thromboplastin time (APTT), ecarin coagulation time (ECT) and thrombin coagulation time (TCT) were used as plasma biomarkers of anticoagulant effect. Dalteparin was used as a reference compound. AR-H067637, given by continuous infusion, displayed a dose-dependent antithrombotic effect, with 50% inhibition (IC50) of thrombus size in venous and arterial thrombosis models obtained at plasma concentrations of 0.13 μM and 0.55 μM, respectively, without increased bleeding. Dose-dependent increased bleeding and blood loss were seen at plasma concentrations ≥1 μM AR-H067637. At the highest AR-H067637 plasma concentration tested, bleeding time and blood loss increased two and four times the vehicle group. Addition of ASA moderately potentiated bleeding time and blood loss. APTT, ECT and TCT were dose-dependently prolonged. These studies demonstrate that the DTI AR-H067637 inhibits thrombus formation in rat venous and arterial thrombosis models with no or minor increases in bleeding.
Authors:
S Pehrsson; K Johansson; M Kjaer; M Elg
Related Documents :
16874686 - Vascular access-related thrombotic complications: research hypotheses and therapeutic s...
7091926 - Strokes in children. their relationship to intrinsic pathology of the carotid artery.
8465516 - Thrombendarteriitis pulmonalis carcinomatosa ceelen: an immunohistological investigation.
7245036 - Antithrombin deficiency--a cause of unexplained thrombosis in vascular surgery.
17307456 - Optimal end-organ protection for thoracic and thoracoabdominal aortic aneurysm repair u...
7819626 - Cerebral complications after coronary bypass grafting.
Publication Detail:
Type:  Journal Article     Date:  2010-08-30
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  104     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1242-9     Citation Subset:  IM    
Affiliation:
AstraZeneca R&D, Bioscience, SE 431 83 Mölndal, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2-5.
Next Document:  Non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants an...